DE3934366A1 - Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum - Google Patents

Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum

Info

Publication number
DE3934366A1
DE3934366A1 DE3934366A DE3934366A DE3934366A1 DE 3934366 A1 DE3934366 A1 DE 3934366A1 DE 3934366 A DE3934366 A DE 3934366A DE 3934366 A DE3934366 A DE 3934366A DE 3934366 A1 DE3934366 A1 DE 3934366A1
Authority
DE
Germany
Prior art keywords
hiv
virus
vaccine
infections
protection against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE3934366A
Other languages
German (de)
English (en)
Other versions
DE3934366C2 (enExample
Inventor
Ursula Dr Dietrich
Michalina Dipl Biol Adamski
Hagen Von Dipl Biol Briesen
Herbert Dr Kuehnel
Helga Prof Ruebsamen-Waigmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Original Assignee
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6391493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3934366(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemotherapeutisches Forschungsinstitut Georg Speyer Haus filed Critical Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Priority to DE3934366A priority Critical patent/DE3934366A1/de
Priority to PCT/EP1990/001729 priority patent/WO1991005567A1/de
Priority to JP51473190A priority patent/JP3152433B2/ja
Priority to DK90915992.3T priority patent/DK0495896T3/da
Priority to EP90915992A priority patent/EP0495896B1/de
Priority to DE59006080T priority patent/DE59006080D1/de
Priority to AT90915992T priority patent/ATE106748T1/de
Priority to ES90915992T priority patent/ES2055922T3/es
Publication of DE3934366A1 publication Critical patent/DE3934366A1/de
Publication of DE3934366C2 publication Critical patent/DE3934366C2/de
Application granted granted Critical
Priority to US08/968,689 priority patent/US5861243A/en
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE3934366A 1989-10-14 1989-10-14 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum Granted DE3934366A1 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE3934366A DE3934366A1 (de) 1989-10-14 1989-10-14 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
EP90915992A EP0495896B1 (de) 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
JP51473190A JP3152433B2 (ja) 1989-10-14 1990-10-12 Ｈｉｖ感染防止用ワクチンおよび免疫療法剤
DK90915992.3T DK0495896T3 (da) 1989-10-14 1990-10-12 Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel
PCT/EP1990/001729 WO1991005567A1 (de) 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
DE59006080T DE59006080D1 (de) 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.
AT90915992T ATE106748T1 (de) 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.
ES90915992T ES2055922T3 (es) 1989-10-14 1990-10-12 Vacunas para la proteccion ante infecciones por virus hiv, procedimiento para su preparacion y su uso como agente de diagnostico e inmunoterapeutico.
US08/968,689 US5861243A (en) 1989-10-14 1997-11-12 Vaccine for protection against HIV infections, process for preparing same and their use as diagnostic and agent immunotherapeutic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3934366A DE3934366A1 (de) 1989-10-14 1989-10-14 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum

Publications (2)

Publication Number Publication Date
DE3934366A1 true DE3934366A1 (de) 1991-04-18
DE3934366C2 DE3934366C2 (enExample) 1991-11-07

Family

ID=6391493

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3934366A Granted DE3934366A1 (de) 1989-10-14 1989-10-14 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
DE59006080T Revoked DE59006080D1 (de) 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE59006080T Revoked DE59006080D1 (de) 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.

Country Status (8)

Country Link
US (1) US5861243A (enExample)
EP (1) EP0495896B1 (enExample)
JP (1) JP3152433B2 (enExample)
AT (1) ATE106748T1 (enExample)
DE (2) DE3934366A1 (enExample)
DK (1) DK0495896T3 (enExample)
ES (1) ES2055922T3 (enExample)
WO (1) WO1991005567A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0814826A4 (en) * 1995-03-17 2000-01-19 Univ California COMPOSITIONS AND METHODS FOR REDUCING THE ADHESION OF SICK RED BLOOD CELLS
EP0868536A4 (en) * 1995-12-20 2001-11-07 Subsidiary N0 3 Inc GENETIC SUPPRESSOR ELEMENTS AGAINST HIV
EP1849869A3 (fr) * 1994-10-20 2011-05-18 Institut Pasteur Séquences nucléotidiques d'antigènes rétroviraux VIH-1 groupe (ou sous-groupe) 0

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047073A1 (en) * 1990-07-19 1992-01-20 William J. Leanza Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
DE69830395T2 (de) * 1997-03-20 2006-01-26 Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara Iterative resequenzierung
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
AU778809B2 (en) 1999-03-29 2004-12-23 Statens Serum Institut Method for producing a nucleotide sequence construct with optimised codons for an HIV genetic vaccine based on primary, early HIV isolate and synthetic envelope BX08 constructs
US7611721B1 (en) 1999-05-13 2009-11-03 Wyeth Holdings Corporation Adjuvant combination formulations
WO2001047955A2 (en) * 1999-12-23 2001-07-05 Medical Research Council Improvements in or relating to immune responses to hiv
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
PE20020530A1 (es) * 2000-11-10 2002-06-18 Wyeth Corp Formulaciones de combinacion adyuvante
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
AU2006214563B2 (en) 2005-02-15 2011-08-18 Thymon, L.L.C. Methods and compositions for impairing multiplication of HIV-1
US20100275278A1 (en) * 2006-02-03 2010-10-28 Karp Nelson M Animal model for hiv induced disease
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
CN115124628B (zh) * 2021-03-27 2023-03-31 中国科学院昆明植物研究所 一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347365A2 (en) * 1988-06-14 1989-12-20 QIAGEN GmbH HIV-2 virus variants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2104556T3 (es) * 1987-01-16 1997-10-16 Pasteur Institut Peptidos que tienen propiedades inmunologicas de hiv-2.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347365A2 (en) * 1988-06-14 1989-12-20 QIAGEN GmbH HIV-2 virus variants

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1849869A3 (fr) * 1994-10-20 2011-05-18 Institut Pasteur Séquences nucléotidiques d'antigènes rétroviraux VIH-1 groupe (ou sous-groupe) 0
EP0814826A4 (en) * 1995-03-17 2000-01-19 Univ California COMPOSITIONS AND METHODS FOR REDUCING THE ADHESION OF SICK RED BLOOD CELLS
US6124262A (en) * 1995-03-17 2000-09-26 The Regents Of The University Of California Compositions and methods for reducing adhesiveness of defective red blood cells
EP0868536A4 (en) * 1995-12-20 2001-11-07 Subsidiary N0 3 Inc GENETIC SUPPRESSOR ELEMENTS AGAINST HIV

Also Published As

Publication number Publication date
ATE106748T1 (de) 1994-06-15
DE3934366C2 (enExample) 1991-11-07
JPH05505389A (ja) 1993-08-12
DE59006080D1 (de) 1994-07-14
WO1991005567A1 (de) 1991-05-02
JP3152433B2 (ja) 2001-04-03
EP0495896A1 (de) 1992-07-29
EP0495896B1 (de) 1994-06-08
DK0495896T3 (da) 1994-10-10
US5861243A (en) 1999-01-19
ES2055922T3 (es) 1994-09-01

Similar Documents

Publication Publication Date Title
DE3934366C2 (enExample)
DE69527089T2 (de) Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe
DE3855947T2 (de) Peptide mit den immunologischen Eigenschaften von HIV-2
EP0591914B1 (de) Retrovirus aus der HIV-Gruppe und dessen Verwendung
DE3588251T2 (de) DNS-Fragmente des GAG-Gens von LAV
DE69222303T2 (de) Kationisierte antikörper gegen intrazelluläre eiweisse
DE69835031T2 (de) Neue anti-hiv immunogene (toxoide), herstellungsverfahren und verwendung zur behandlung und vorbeugung von aids
DE60110822T2 (de) Zubereitung zur immunisierung gegen den aids-virus
DE69230068T2 (de) Immunogene verbindungen mit spezifischem anti-cytokin effekt, methode zur herstellung, pharmazeutische zusammensetzung und reaktionskit der diese enthält
DE69129034T3 (de) Molekulare klone von hiv-1 und deren verwendung
DE3650032T2 (de) Anticytomegaloviraler menschlicher monoklonaler antikörper und dessen herstellung.
DE69028951T2 (de) Oligonukleotiden-Sequenzen zur Amplifizierung von HIV-2 und SIV Retrovirusgenomen, ihre Verwendung zur In-vitro-Diagnostik von durch diese Viren verursachten Infektionen
DE69610295T2 (de) Von einem retroviralen regulationsprotein abstammende, detoxifierte immunogene, dagegen gerichtete antikörper, verfahren zur deren herstellung und diese immunogene oder antikörper enthaltende, pharmazeutische zusammensetzungen.
DE4006630A1 (de) Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
EP1200126A1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von virusinfektionen
DE69434961T2 (de) Funktion und aktivität des viralen proteins r (vpr)
DE69830325T2 (de) Peptide, die vom Gen env des FIV (Virus der felinen Immuneffizienz) abgeleitet sind sowie auf ihre immunprotektiven Anwendungen
DE69213325T2 (de) Gegen das menschliche Immunschwäche-Virus gerichtetes Immunpräparat
EP0658119B1 (de) Neue hiv-1-virusisolate eines subtyps und seine differentielle diagnostik, vakzine gegen hiv-1-virusinfektionen dieses subtyps und verfahren zu ihrer herstellung, verwendung der hiv-1-virusisolate
DE69615685T2 (de) Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen
CH664575A5 (de) Verfahren zur herstellung eines interferonpraeparates mit antiviraler aktivitaet.
DE68926813T2 (de) Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide
WO1998019160A2 (de) VERFAHREN ZUR INDIREKTEN BESTIMMUNG DER TYP I INTERFERON-PRODUKTION IN VIVO MITTELS ANTIKÖRPER GEGEN HUMANE Mx-PROTEINE SOWIE ANTIKÖRPER HIERZU
DE69112392T2 (de) Bcrf1-antagonisten zur behandlung von epstein-barr-virus-infektionen.
EP0486917A2 (de) Antivirale Aktivität des vom adeno-assoziierten Virus Typ 2 codierten rep-Gens

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee